Menlo Therapeutics Inc., a biopharmaceutical firm focused on dermatology therapies, announced Tuesday it has appointed Andrew Saik as chief financial officer and treasurer, effective immediately.
Saik, who will report to CEO David Domzalski and be based at the company’s headquarters in Bridgewater, will be responsible for heading Menlo’s global financials including financial planning and analysis, investor relations, accounting, tax, treasury, supply chain and information technology.
“Andrew is an accomplished CFO and brings a wealth of experience to the senior management team at Menlo,” Domzalski said. “His experience includes shaping financial strategy, leading successful M&A transactions, integrating global company and product acquisitions, cash management, and investor relations. In addition, his broad global business expertise, which encompasses commercial pharmaceutical operations, manufacturing and supply chain management, will bring depth and breadth to Menlo’s executive leadership team at this time of growth for our company.”
Saik has more than 20 years of experience in accounting, finance and general management, most recently serving as CFO for PDS Biotechnology Inc., formerly Edge Therapeutics.
The Princeton-based clinical-stage immuno-oncology company had announced Saik’s departure as CFO and a director on Monday. It named Frank Bedu-Addo, CEO and president, as interim principal financial officer and Janetta Trochimiuk, controller, as interim principal accounting officer.
“On behalf of our board of directors, we would like to thank Andrew for his service and contributions as we transitioned to a public company and successfully bolstered our balance sheet with the recent capital raise based on our promising Versamune platform technology. We wish him continued success in his future endeavors and look forward to announcing a permanent successor in the near term,” Bedu-Addo said.
Before joining PDS following its March 2019 merger with Edge, Saik was CFO at Vertice Pharma LLC and then CFO at Auxilium Pharmaceuticals Inc. Prior to that, he was senior vice president, finance and treasurer at Endo Health Solutions Inc. He also served in senior financial roles at Valeant Pharmaceuticals International.
“Menlo is positioned to be a market leader in therapeutic dermatology, and I am thrilled to be joining at this exciting time. We have a differentiated commercial-stage product in acne and a compelling portfolio of late stage dermatology assets. Having had previous experience with dermatology products I recognize that companies such as Menlo, with differentiated offerings and the ability to commercialize multiple products in the near-term, can help lead successful consolidation in the sector. The Company has shown a commitment to serving the needs of dermatology patients and I look forward to applying my experience through the next phase of growth,” Saik said.
